ClinicalTrials.gg
TerminatedNCT05516498ZEALUpdated Sep 25, 2026Results posted

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

A Phase 2 interventional study of Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) and Part A: zibotentan (dose B) + dapagliflozin in Liver Cirrhosis, sponsored by AstraZeneca. Terminated at 50 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by AstraZeneca · Phase 2, Interventional, and Screening

Why this study was terminated
The study was ended earlier than planned due to a sponsor decision.
Updated Sep 25, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
2nd of 11
205 · median 40
Started
2022
with 1 other
Phase 2
6 of 11
1 open now
Registered
2nd of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 2nd registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.

Read the detailed description

Part A will assess the efficacy, safety, and tolerability of the combination of B mg zibotentan and 10 mg dapagliflozin versus placebo in participants with Child-Pugh A cirrhosis with features of portal hypertension and with no history of decompensation events.

If the safety profile is determined to be acceptable at the conclusion of Part A, Part B will investigate efficacy, safety, and tolerability of A mg, B mg, or C mg zibotentan combined with 10 mg dapagliflozin and of 10 mg dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension. Part B will include a broader range of Child- Pugh A and Child-Pugh B cirrhosis participants, including those with more severe disease, a history of decompensation events, or current ascites.

The study will be conducted in approximately 30 to 45 study centres in North America, Asia, and Europe.

03

Conditions studied

  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Study principal inclusion criteria For both Part A and Part B

  1. No current or prior (within 1 month of enrolment) medical treatment with an SGLT2 inhibitor or ERAs.
  2. On no or a stable dose of beta blockers, with no major dose changes within 1 month prior to the first dose of study intervention.
  3. Provision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.
  4. Female participants of non- confirmed at screening by fulfilling one of the following criteria:

    1. : defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments; and also, FSH levels in the post-menopausal range by central laboratory.
    2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  5. Female participants must have a negative pregnancy test at screening and must not be lactating

Part A participants who have the following:

  1. Clinical and/or histological diagnosis of cirrhosis with either (i) features of portal hypertension or (ii) liver stiffness ≥ 21 kPa.
  2. MELD score \< 15.
  3. score ≤ 6.
  4. No clinically evident ascites.
  5. No evidence of worsening of hepatic function (eg, no change in signs, symptoms, or laboratory parameters of hepatic disease status) within the last month prior to dosing, as determined by the investigator or usual practitioner.
  6. HVPG recording of good enough quality as judged by a central reader.

Part B participants who have the following:

  1. Clinical and/or histological diagnosis of cirrhosis and either history of decompensation or compensated cirrhosis with signs of clinically significant portal hypertension.
  2. HVPG recording of good enough quality and HVPG > 10 mmHg, as judged by a central reader.
  3. MELD score \< 15.
  4. Child-Pugh score \< 10.
  5. No ascites or ascites up to grade 2 without change in diuretic treatment within the last month prior to first dose and no paracentesis within the last month or planned paracentesis in the next 4 months at screening.
  6. No evidence of worsening of hepatic function (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status) within the last month prior to dosing, as determined by the investigator or usual practitioner.

Study principal exclusion criteria:

  1. Any evidence of a clinically significant disease which in the investigator's opinion makes it undesirable for the participant to participate in the study.
  2. Liver cirrhosis caused by chronic cholestatic liver disease
  3. or AST ≥ 150 U/L and/or total ≥ 3 ×
  4. Acute liver injury caused by drug toxicity or by an infection.
  5. Any history of hepatocellular carcinoma.
  6. Liver transplant or expected liver transplantation within 6 months of screening.
  7. History of TIPS or a planned TIPS within 6 months from enrolment into the study.
  8. Active treatment for within the last 1 year or antiviral therapy for less than 1 year.
  9. Participants with T1DM.

Medical Conditions (Part A only)

  1. > 1.5.
  2. Serum/plasma levels of albumin ≤ 35 g/L.
  3. count \< 75 × 109/L.
  4. History of ascites
  5. History of hepatic hydrothorax
  6. History of portopulmonary syndrome
  7. History of hepatic encephalopathy
  8. History of variceal haemorrhage
  9. History of acute kidney injury
  10. History of heart failure, including high output heart failure (eg, due to hyperthyroidism or Paget's disease)

Medical Conditions (Part B only)

  1. INR > 1.7.
  2. Serum/plasma levels of albumin ≤ 28 g/L.
  3. Platelet count \< 50 × /109L.
  4. Acute kidney injury within 3 months of screening.
  5. History of encephalopathy of West Haven grade 2 or higher within 6 months prior to screening.
  6. History of variceal haemorrhage within 6 months prior to screening.
  7. functional heart failure class III or IV or with unstable heart failure requiring hospitalisation for optimisation of heart failure treatment and who are not yet stable on heart failure therapy within 6 months prior to screening.
  8. Heart failure due to cardiomyopathies that would primarily require specific other treatment: eg, cardiomyopathy due to pericardial disease, amyloidosis or other infiltrative diseases, cardiomyopathy related to congenital heart disease, primary hypertrophic cardiomyopathy, cardiomyopathy related to toxic or infective conditions (ie, chemotherapy, infective myocarditis, septic cardiomyopathy).
  9. High output heart failure (eg, due to hyperthyroidism or Paget's disease).
  10. Heart failure due to primary cardiac valvular disease/dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Part A: Treatment Group 1

    Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks.

    Drug: Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)

  • Experimental
    Part A: Treatment Group 2

    Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 6 weeks.

    Drug: Part A: zibotentan (dose B) + dapagliflozin

  • Experimental
    Part B: Treatment Group 1

    Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 16 weeks.

    Drug: Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)

  • Experimental
    Part B: Treatment Group 2

    Participants will receive once daily dose of placebo matching zibotentan capsule + dapagliflozin tablet for 16 weeks.

    Drug: Part B: placebo (matching zibotentan capsule) + dapagliflozin

  • Experimental
    Part B: Treatment Group 3

    Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.

    Drug: Part B: zibotentan (dose A) + dapagliflozin

  • Experimental
    Part B: Treatment Group 4

    Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.

    Drug: Part B: zibotentan (dose B) + dapagliflozin

  • Experimental
    Part B: Treatment Group 5

    Participants will receive once daily dose of zibotentan capsule + dapagliflozin tablet for 16 weeks.

    Drug: Part B: zibotentan (dose C) + dapagliflozin

Interventions

  • DrugPart A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)

    placebo capsule (matching zibotentan capsule) placebo tablet (matching dapagliflozin tablet)

  • DrugPart A: zibotentan (dose B) + dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    zibotentan capsule dapagliflozin tablet

  • DrugPart B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)

    placebo capsule (matching zibotentan capsule) placebo tablet (matching dapagliflozin tablet)

  • DrugPart B: placebo (matching zibotentan capsule) + dapagliflozin

    placebo capsule (matching zibotentan capsule) dapagliflozin tablet

  • DrugPart B: zibotentan (dose A) + dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    zibotentan capsule dapagliflozin tablet

  • DrugPart B: zibotentan (dose B) + dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    zibotentan capsule dapagliflozin tablet

  • DrugPart B: zibotentan (dose C) + dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    zibotentan capsule dapagliflozin tablet

06

What researchers measure

Primary outcomes

  1. Absolute Change in HVPG From Baseline to Week 6, Part A

    Absolute change in Hepatic venous pressure gradient from baseline to week 6.

    Time frame: From Baseline to Week 6

  2. Absolute Change in HVPG From Baseline to Week 6, Part B

    Absolute change in Hepatic venous pressure gradient from baseline to week 6.

    Time frame: From Baseline to Week 6

Secondary outcomes

  1. HVPG Percentage Change From Baseline to Week 6, Part A

    Hepatic venous pressure gradient percentage change from baseline to week 6, Part A.

    Time frame: From Baseline to Week 6

  2. HVPG Percentage Change From Baseline to Week 6, Part B

    Hepatic venous pressure gradient percentage change from baseline to week 6, Part B.

    Time frame: From baseline to week 6

  3. Number of Participants With HVPG Response at Week 6, Part A

    A HVPG responder is defined as a subject having \<10 mmHg at week 6 if baseline HVPG \>=10 or a reduction of \>=1.5 mmHg from baseline to week 6. n: Number of subjects in analysis. N: Number of subjects per treatment group.

    Time frame: From baseline to week 6

  4. Number of Participants With HVPG Response at Week 6, Part B

    A HVPG responder in Part B is defined as a subject having at least 20% decrease or a reduction to or below 12 mmHg if baseline HVPG \> 12 mmHG from baseline to Week 6.

    Time frame: From baseline to Week 6

  5. Change in Body Weight (kg) Over Time Course of Study, Part A

    The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.

    Time frame: From baseline to Week 6

  6. Change in Body Weight (kg) Over Time Course of Study, Part B

    The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.

    Time frame: From baseline to Week 6 and Week 16

  7. Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6, Part A

    Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part A. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.

    Time frame: From baseline to Week 6

  8. Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6 and Week 16, Part B

    Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part B. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.

    Time frame: From Baseline to Week 6 and Week 16

  9. Change in Total Body Water From Baseline to Week 6, Part A

    Change in total body water from baseline to Week 6, Part A. The analysis is performed using MMRM.

    Time frame: From Baseline to Week 6

  10. Change in Total Body Water From Baseline to Week 6 and Week 16, Part B

    Change in total body water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.

    Time frame: From Baseline to Week 6 and Week 16

  11. Change in Extracellular Water From Baseline to Week 6, Part A

    Change in extracellular water from baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

    Time frame: From baseline to Week 6

  12. Change in Extracellular Water From Baseline to Week 6 and Week 16, Part B

    Change in extracellular water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

    Time frame: From Baseline to Week 6 and to Week 16

  13. Change in Intracellular Water From Baseline to Week 6, Part A

    Change in intracellular water from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

    Time frame: From Baseline to Week 6

  14. Change in Intracellular Water From Baseline to Week 6 and Week 16, Part B

    Change in intracellular water from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

    Time frame: From Baseline to Week 6 and Week 16

  15. Change in Total Body Fat Mass From Baseline to Week 6, Part A

    Change in total body fat mass from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

    Time frame: From baseline to Week 6

  16. Change in Total Body Fat Mass From Baseline to Week 6 and Week 16, Part B

    Change in total body fat mass from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

    Time frame: From Baseline to Week 6 and Week 16

  17. Change in Systolic Blood Pressure From Baseline to Week 6, Part A

    Change in systolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.

    Time frame: From Baseline to Week 6

  18. Change in Systolic Blood Pressure From Baseline to Week 6 and Week 16, Part B

    Change in systolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.

    Time frame: From baseline to Week 6 and Week 16

  19. Change in Diastolic Blood Pressure From Baseline to Week 6, Part A

    Change in diastolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.

    Time frame: From Baseline to Week 6

  20. Change in Diastolic Blood Pressure From Baseline to Week 6 and Week 16, Part B

    Change in diastolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.

    Time frame: From baseline to Week 6 and Week 16

07

Results

Posted Sep 25, 2026
Limitations and caveats
For the secondary endpoint #8: Change in total dosage of loop-diuretic equivalents use from baseline to Week 6 and Week 16, Part B. Because the standard error in the placebo group was zero, the corresponding p-values and confidence intervals (CIs) could not be reliably estimated, although SAS reported the p-values in the output.

Participant flow

This study was conducted at a total of 50 study centers in 15 countries: Australia (1), Austria (1), Belgium (1), China (4), Czech Republic (2), Denmark (4), France (4), Germany (5), Netherlands (1), Romania (1), Spain (7), Switzerland (3), Taiwan (2), United Kingdom (3) and United States (11). First subject enrolled: 31 Oct 2022 and Last subject last visit: 17 Jul 2025.

Participant flow — Overall Study
MilestonePart A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Started14143535363635
Completed13132425241925
Not completed111110121710
Withdrew: Study terminated by sponsor0086587
Withdrew: Physician decision0010011
Withdrew: Withdrawn from study due to subject decision0000001
Withdrew: Adverse event0013551
Withdrew: Withdrawal by subject1100030
Withdrew: Subjects randomised, not treated0011200

Outcome measures

PrimaryAbsolute Change in HVPG From Baseline to Week 6, Part A

Absolute change in Hepatic venous pressure gradient from baseline to week 6.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · mmHg
Absolute Change in HVPG From Baseline to Week 6, Part A
mmHgPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Absolute Change in HVPG From Baseline to Week 6, Part A0.13 (-0.79 to 1.05)-0.89 (-1.81 to 0.03)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · ANCOVA · p = 0.896 · Mean difference (final values): 1.02 · 90% CI -0.31 to 2.35
PrimaryAbsolute Change in HVPG From Baseline to Week 6, Part B

Absolute change in Hepatic venous pressure gradient from baseline to week 6.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · mmHg
Absolute Change in HVPG From Baseline to Week 6, Part B
mmHgPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Absolute Change in HVPG From Baseline to Week 6, Part B-0.56 (-1.34 to 0.22)-1.48 (-2.31 to -0.64)0.02 (-0.79 to 0.83)-1.02 (-1.93 to -0.11)-1.37 (-2.16 to -0.59)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · ANCOVA · p = 0.885 · Mean difference (final values): 0.81 · 90% CI -0.30 to 1.92
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · ANCOVA · p = 0.442 · Mean difference (final values): -0.10 · 90% CI -1.26 to 1.05
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · ANCOVA · p = 0.979 · Mean difference (final values): 1.39 · 90% CI 0.27 to 2.52
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · ANCOVA · p = 0.683 · Mean difference (final values): 0.35 · 90% CI -0.86 to 1.57
SecondaryHVPG Percentage Change From Baseline to Week 6, Part A

Hepatic venous pressure gradient percentage change from baseline to week 6, Part A.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · percentage change
HVPG Percentage Change From Baseline to Week 6, Part A
percentage changePart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
HVPG Percentage Change From Baseline to Week 6, Part A3.20 (-4.41 to 10.82)-6.21 (-13.75 to 1.33)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · ANCOVA · p = 0.921 · Mean difference (final values): 9.41 · 90% CI -1.56 to 20.39
SecondaryHVPG Percentage Change From Baseline to Week 6, Part B

Hepatic venous pressure gradient percentage change from baseline to week 6, Part B.

Time frame:
From baseline to week 6
Reported as:
Least squares mean · percentage change
HVPG Percentage Change From Baseline to Week 6, Part B
percentage changePart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5mg/10 mgPart B Placebo
HVPG Percentage Change From Baseline to Week 6, Part B-3.62 (-8.54 to 1.31)-8.93 (-14.33 to -3.52)0.29 (-4.81 to 5.39)-5.66 (-11.26 to -0.06)-7.64 (-12.56 to -2.71)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · ANCOVA · p = 0.828 · Mean difference (final values): 4.02 · 90% CI -2.96 to 10.99
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · ANCOVA · p = 0.386 · Mean difference (final values): -1.29 · 90% CI -8.64 to 6.05
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · ANCOVA · p = 0.967 · Mean difference (final values): 7.93 · 90% CI 0.85 to 15.00
  • Part B Zibo/Dapa 5mg/10 mg vs Part B Placebo · ANCOVA · p = 0.667 · Mean difference (final values): 1.98 · 90% CI -5.53 to 9.48
SecondaryNumber of Participants With HVPG Response at Week 6, Part A

A HVPG responder is defined as a subject having \<10 mmHg at week 6 if baseline HVPG \>=10 or a reduction of \>=1.5 mmHg from baseline to week 6. n: Number of subjects in analysis. N: Number of subjects per treatment group.

Time frame:
From baseline to week 6
Reported as:
Count of participants · Participants
Number of Participants With HVPG Response at Week 6, Part A
ParticipantsPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Number of Participants With HVPG Response at Week 6, Part A54
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Fisher Exact · p = 0.500 · Risk difference (rd): 0.08 · 90% CI -0.25 to 0.39Only subjects with non-missing HVPG values are included in the analysis.
SecondaryNumber of Participants With HVPG Response at Week 6, Part B

A HVPG responder in Part B is defined as a subject having at least 20% decrease or a reduction to or below 12 mmHg if baseline HVPG \> 12 mmHG from baseline to Week 6.

Time frame:
From baseline to Week 6
Reported as:
Count of participants · Participants
Number of Participants With HVPG Response at Week 6, Part B
ParticipantsPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Number of Participants With HVPG Response at Week 6, Part B810479
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Fisher Exact · p = 0.712 · Risk difference (rd): -0.03 · 90% CI -0.21 to 0.15Only participants with non-missing HVPG values are included in the analysis.
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Fisher Exact · p = 0.372 · Risk difference (rd): 0.07 · 90% CI -0.13 to 0.26Only participants with non-missing HVPG values are included in the analysis.
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Fisher Exact · p = 0.960 · Risk difference (rd): -0.14 · 90% CI -0.30 to 0.03Only participants with non-missing HVPG values are included in the analysis.
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Fisher Exact · p = 0.598 · Risk difference (rd): 0.00 · 90% CI -0.19 to 0.21Only participants with non-missing HVPG values are included in the analysis.
SecondaryChange in Body Weight (kg) Over Time Course of Study, Part A

The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.

Time frame:
From baseline to Week 6
Reported as:
Least squares mean · kg
Change in Body Weight (kg) Over Time Course of Study, Part A
kgPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Body Weight (kg) Over Time Course of Study, Part A-1.01 (-1.75 to -0.27)-0.25 (-1.06 to 0.56)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.124 · Mean difference (final values): -0.76 · 90% CI -1.86 to 0.34
SecondaryChange in Body Weight (kg) Over Time Course of Study, Part B

The analysis is performed using MMRM. The model includes the continuous covariate of the Baseline measurements as the fixed effect covariate and fixed categorical effects of treatment group, visit, and treatmentby-visit interaction.

Time frame:
From baseline to Week 6 and Week 16
Reported as:
Least squares mean · kg
Change in Body Weight (kg) Over Time Course of Study, Part B
kgPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-0.74 (-1.41 to -0.08)-0.21 (-0.89 to 0.46)-0.73 (-1.41 to -0.05)-0.87 (-1.55 to -0.18)0.15 (-0.51 to 0.80)
Week 16-1.13 (-2.07 to -0.18)-1.31 (-2.24 to -0.38)-0.63 (-1.58 to 0.31)-1.27 (-2.27 to -0.27)1.02 (0.11 to 1.93)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.059 · Mean difference (final values): -0.89 · 90% CI -1.82 to 0.05
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.263 · Mean difference (final values): -0.36 · 90% CI -1.30 to 0.58
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.063 · Mean difference (final values): -0.88 · 90% CI -1.82 to 0.07
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.040 · Mean difference (final values): -1.01 · 90% CI -1.96 to -0.06
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -2.15 · 90% CI -3.46 to -0.84
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -2.33 · 90% CI -3.63 to -1.03
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.019 · Mean difference (final values): -1.65 · 90% CI -2.97 to -0.34
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -2.29 · 90% CI -3.64 to -0.94
SecondaryChange in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6, Part A

Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part A. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.

Time frame:
From baseline to Week 6
Reported as:
Least squares mean · 40 mg furosemide equivalents
Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6, Part A
40 mg furosemide equivalentsPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6, Part A0.8 (0.0 to 1.6)0.0 (-0.8 to 0.8)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.880 · Mean difference (final values): 0.8 · 90% CI -0.3 to 1.9
SecondaryChange in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6 and Week 16, Part B

Change in total dosage of loop-diuretic equivalents use from baseline to Week 6, Part B. A loop-diuretic equivalent is based on 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid.

Time frame:
From Baseline to Week 6 and Week 16
Reported as:
Least squares mean · 40 mg furosemide equivalents
Change in Total Dosage of Loop-diuretic Equivalents Use From Baseline to Week 6 and Week 16, Part B
40 mg furosemide equivalentsPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-0.018 (-2.804 to 2.769)2.931 (-1.226 to 7.087)2.894 (0.072 to 5.717)7.084 (3.390 to 10.777)-0.044 (NA to NA)
Week 162.838 (-3.898 to 9.573)9.462 (-2.177 to 21.101)11.154 (4.274 to 18.033)23.629 (13.404 to 33.855)4.344 (NA to NA)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 0.026
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 2.975
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 2.939
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 7.128
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): -1.188
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 5.018
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 4.748
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · Mean difference (final values): 10.537
SecondaryChange in Total Body Water From Baseline to Week 6, Part A

Change in total body water from baseline to Week 6, Part A. The analysis is performed using MMRM.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · L
Change in Total Body Water From Baseline to Week 6, Part A
LPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Total Body Water From Baseline to Week 6, Part A0.7 (0 to 1.5)0.5 (-0.3 to 1.3)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.616 · Mean difference (final values): 0.2 · 90% CI -0.9 to 1.3
SecondaryChange in Total Body Water From Baseline to Week 6 and Week 16, Part B

Change in total body water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.

Time frame:
From Baseline to Week 6 and Week 16
Reported as:
Least squares mean · L
Change in Total Body Water From Baseline to Week 6 and Week 16, Part B
LPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-0.18 (-0.67 to 0.31)0.07 (-0.43 to 0.58)0.48 (-0.02 to 0.98)0.39 (-0.12 to 0.90)-0.12 (-0.61 to 0.36)
Week 16-0.46 (-1.02 to 0.10)0.05 (-0.49 to 0.60)0.80 (0.25 to 1.36)0.48 (-0.13 to 1.08)0.31 (-0.23 to 0.84)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.443 · Mean difference (final values): -0.06 · 90% CI -0.75 to 0.63
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.679 · Mean difference (final values): 0.20 · 90% CI -0.50 to 0.90
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.923 · Mean difference (final values): 0.60 · 90% CI -0.09 to 1.30
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.883 · Mean difference (final values): 0.51 · 90% CI -0.19 to 1.21
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.052 · Mean difference (final values): -0.76 · 90% CI -1.54 to 0.01
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.293 · Mean difference (final values): -0.25 · 90% CI -1.02 to 0.51
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.855 · Mean difference (final values): 0.50 · 90% CI -0.28 to 1.27
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.637 · Mean difference (final values): 0.17 · 90% CI -0.63 to 0.98
SecondaryChange in Extracellular Water From Baseline to Week 6, Part A

Change in extracellular water from baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

Time frame:
From baseline to Week 6
Reported as:
Least squares mean · L
Change in Extracellular Water From Baseline to Week 6, Part A
LPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Extracellular Water From Baseline to Week 6, Part A0.2 (-0.6 to 1.1)1.1 (0.2 to 2.0)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.115 · Mean difference (final values): -0.9 · 90% CI -2.1 to 0.3
SecondaryChange in Extracellular Water From Baseline to Week 6 and Week 16, Part B

Change in extracellular water from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

Time frame:
From Baseline to Week 6 and to Week 16
Reported as:
Least squares mean · L
Change in Extracellular Water From Baseline to Week 6 and Week 16, Part B
LPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-0.14 (-0.39 to 0.10)0.12 (-0.13 to 0.37)0.37 (0.12 to 0.62)0.25 (0.00 to 0.51)-0.09 (-0.33 to 0.15)
Week 16-0.26 (-0.54 to 0.02)0.08 (-0.19 to 0.35)0.36 (0.08 to 0.63)0.50 (0.20 to 0.80)0.11 (-0.15 to 0.38)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.395 · Mean difference (final values): -0.06 · 90% CI -0.40 to 0.29
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.837 · Mean difference (final values): 0.21 · 90% CI -0.14 to 0.55
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.985 · Mean difference (final values): 0.46 · 90% CI 0.11 to 0.80
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.947 · Mean difference (final values): 0.34 · 90% CI -0.01 to 0.69
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.055 · Mean difference (final values): -0.37 · 90% CI -0.76 to 0.01
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.438 · Mean difference (final values): -0.04 · 90% CI -0.42 to 0.35
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.851 · Mean difference (final values): 0.24 · 90% CI -0.14 to 0.63
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.941 · Mean difference (final values): 0.38 · 90% CI -0.02 to 0.79
SecondaryChange in Intracellular Water From Baseline to Week 6, Part A

Change in intracellular water from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · L
Change in Intracellular Water From Baseline to Week 6, Part A
LPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Intracellular Water From Baseline to Week 6, Part A0.1 (-0.1 to 1.3)-0.7 (-1.9 to 0.4)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.824 · Mean difference (final values): 0.9 · 90% CI -0.7 to 2.5
SecondaryChange in Intracellular Water From Baseline to Week 6 and Week 16, Part B

Change in intracellular water from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

Time frame:
From Baseline to Week 6 and Week 16
Reported as:
Least squares mean · L
Change in Intracellular Water From Baseline to Week 6 and Week 16, Part B
LPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-0.02 (-0.30 to 0.26)-0.10 (-0.39 to 0.18)0.16 (-0.12 to 0.45)0.10 (-0.19 to 0.39)-0.06 (-0.34 to 0.21)
Week 16-0.21 (-0.50 to 0.08)-0.02 (-0.30 to 0.26)0.15 (-0.14 to 0.44)0.03 (-0.28 to 0.34)0.16 (-0.12 to 0.43)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.569 · Mean difference (final values): 0.04 · 90% CI -0.35 to 0.44
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.435 · Mean difference (final values): -0.04 · 90% CI -0.44 to 0.36
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.825 · Mean difference (final values): 0.23 · 90% CI -0.17 to 0.62
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.746 · Mean difference (final values): 0.16 · 90% CI -0.24 to 0.56
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.065 · Mean difference (final values): -0.37 · 90% CI -0.77 to 0.03
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.230 · Mean difference (final values): -0.18 · 90% CI -0.57 to 0.22
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.487 · Mean difference (final values): -0.01 · 90% CI -0.41 to 0.39
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.309 · Mean difference (final values): -0.13 · 90% CI -0.54 to 0.29
SecondaryChange in Total Body Fat Mass From Baseline to Week 6, Part A

Change in total body fat mass from Baseline to Week 6, Part A. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

Time frame:
From baseline to Week 6
Reported as:
Least squares mean · kg
Change in Total Body Fat Mass From Baseline to Week 6, Part A
kgPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Total Body Fat Mass From Baseline to Week 6, Part A1.9 (-2.5 to 6.2)0.1 (-4.7 to 5.0)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.673 · Mean difference (final values): 1.7 · 90% CI -4.8 to 8.3
SecondaryChange in Total Body Fat Mass From Baseline to Week 6 and Week 16, Part B

Change in total body fat mass from Baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM. Bioimpedance spectroscopy (BIS) was performed at the study centre to monitor body water volumes and body fat mass.

Time frame:
From Baseline to Week 6 and Week 16
Reported as:
Least squares mean · kg
Change in Total Body Fat Mass From Baseline to Week 6 and Week 16, Part B
kgPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-0.91 (-3.64 to 1.82)0.58 (-2.21 to 3.37)-5.86 (-8.63 to -3.10)-4.78 (-7.55 to -2.00)0.72 (-1.97 to 3.41)
Week 16-1.69 (-4.69 to 1.32)-4.54 (-7.52 to -1.56)-5.58 (-8.59 to -2.57)-6.42 (-9.66 to -3.18)2.35 (-0.56 to 5.26)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.241 · Mean difference (final values): -1.63 · 90% CI -5.46 to 2.20
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.476 · Mean difference (final values): -0.14 · 90% CI -4.02 to 3.74
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -6.59 · 90% CI -10.45 to -2.73
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.010 · Mean difference (final values): -5.50 · 90% CI -9.37 to -1.63
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.056 · Mean difference (final values): -4.03 · 90% CI -8.21 to 0.15
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -6.89 · 90% CI -11.05 to -2.72
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.001 · Mean difference (final values): -7.93 · 90% CI -12.11 to -3.74
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -8.77 · 90% CI -13.12 to -4.41
SecondaryChange in Systolic Blood Pressure From Baseline to Week 6, Part A

Change in systolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · mmHg
Change in Systolic Blood Pressure From Baseline to Week 6, Part A
mmHgPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Systolic Blood Pressure From Baseline to Week 6, Part A-12.4 (-20.4 to -4.4)7.9 (-0.4 to 16.1)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -20.3 · 90% CI -31.8 to -8.7
SecondaryChange in Systolic Blood Pressure From Baseline to Week 6 and Week 16, Part B

Change in systolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.

Time frame:
From baseline to Week 6 and Week 16
Reported as:
Least squares mean · mmHg
Change in Systolic Blood Pressure From Baseline to Week 6 and Week 16, Part B
mmHgPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 6-3.1 (-6.3 to 0.2)-6.0 (-9.3 to -2.7)-8.9 (-12.2 to -5.6)-7.9 (-11.3 to -4.5)-3.3 (-6.5 to -0.1)
Week 16-2.2 (-5.9 to 1.6)-9.1 (-12.7 to -5.5)-6.3 (-10.1 to -2.6)-4.5 (-8.5 to -0.4)-4.6 (-8.2 to -1.1)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.529 · Mean difference (final values): 0.2 · 90% CI -4.3 to 4.8
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.162 · Mean difference (final values): -2.7 · 90% CI -7.3 to 1.8
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.023 · Mean difference (final values): -5.6 · 90% CI -10.2 to -1.0
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.051 · Mean difference (final values): -4.6 · 90% CI -9.3 to 0.0
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.783 · Mean difference (final values): 2.5 · 90% CI -2.7 to 7.6
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.075 · Mean difference (final values): -4.5 · 90% CI -9.5 to 0.6
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.291 · Mean difference (final values): -1.7 · 90% CI -6.9 to 3.4
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.520 · Mean difference (final values): 0.2 · 90% CI -5.2 to 5.5
SecondaryChange in Diastolic Blood Pressure From Baseline to Week 6, Part A

Change in diastolic blood pressure from baseline to Week 6, Part A. The analysis is performed using MMRM.

Time frame:
From Baseline to Week 6
Reported as:
Least squares mean · mmHg
Change in Diastolic Blood Pressure From Baseline to Week 6, Part A
mmHgPart A Zibo/Dapa 2.5 mg/10 mgPart A Placebo
Change in Diastolic Blood Pressure From Baseline to Week 6, Part A-9.0 (-11.7 to -6.4)0.5 (-2.3 to 3.3)
Statistical analysis
  • Part A Zibo/Dapa 2.5 mg/10 mg vs Part A Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -9.5 · 90% CI -13.4 to -5.7
SecondaryChange in Diastolic Blood Pressure From Baseline to Week 6 and Week 16, Part B

Change in diastolic blood pressure from baseline to Week 6 and Week 16, Part B. The analysis is performed using MMRM.

Time frame:
From baseline to Week 6 and Week 16
Reported as:
Least squares mean · mmHg
Change in Diastolic Blood Pressure From Baseline to Week 6 and Week 16, Part B
mmHgPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Week 60.0 (-2.0 to 2.1)-5.5 (-7.6 to -3.5)-6.7 (-8.8 to -4.6)-7.3 (-9.4 to -5.2)-1.6 (-3.6 to 0.4)
Week 16-0.8 (-3.2 to 1.6)-4.5 (-6.8 to -2.2)-4.4 (-6.8 to -2.1)-2.6 (-5.1 to -0.1)-2.1 (-4.4 to 0.1)
Statistical analysis
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.820 · Mean difference (final values): 1.6 · 90% CI -1.3 to 4.5
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.013 · Mean difference (final values): -4.0 · 90% CI -6.9 to -1.0
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -5.1 · 90% CI -8.0 to -2.2
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -5.7 · 90% CI -8.7 to -2.8
  • Part B Dapa 10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.745 · Mean difference (final values): 1.3 · 90% CI -2.0 to 4.6
  • Part B Zibo/Dapa 1 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.111 · Mean difference (final values): -2.4 · 90% CI -5.6 to 0.8
  • Part B Zibo/Dapa 2.5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.124 · Mean difference (final values): -2.3 · 90% CI -5.6 to 1.0
  • Part B Zibo/Dapa 5 mg/10 mg vs Part B Placebo · Mixed Models Analysis · p = 0.406 · Mean difference (final values): -0.5 · 90% CI -3.9 to 2.9

Adverse events

Collected over Time frame for AE: Adverse events are included from the On + off treatment periods, ie, AEs with an onset date on or after the date of first IP through study competition, planned visit date (Day 127).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Zibo/Dapa 2.5 mg/10 mg0/14 (0%)0/14 (0%)10/14 (71.4%)
Part A Placebo0/14 (0%)0/14 (0%)9/14 (64.3%)
Part B Dapa 10 mg0/34 (0%)5/34 (14.7%)20/34 (58.8%)
Part B Zibo/Dapa 1 mg/10 mg0/34 (0%)6/34 (17.6%)17/34 (50%)
Part B Zibo/Dapa 2.5 mg/10 mg0/34 (0%)3/34 (8.8%)21/34 (61.8%)
Part B Zibo/Dapa 5 mg/10 mg0/36 (0%)5/36 (13.9%)26/36 (72.2%)
Part B Placebo0/35 (0%)4/35 (11.4%)16/35 (45.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPart A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
Upper gastrointestinal haemorrhageGastrointestinal disorders0/140/142/340/340/341/360/35
AscitesGastrointestinal disorders0/140/140/342/340/342/360/35
Precancerous lesion of digestive tractGastrointestinal disorders0/140/141/340/340/340/360/35
Cardiac failureCardiac disorders0/140/140/341/340/340/360/35
Escherichia bacteraemiaInfections and infestations0/140/141/340/340/340/360/35
Coronary artery diseaseCardiac disorders0/140/140/341/340/340/360/35
Pneumonia escherichiaInfections and infestations0/140/141/340/340/340/360/35
Radius fractureInjury, poisoning and procedural complications0/140/140/340/341/340/360/35
HyperglycaemiaMetabolism and nutrition disorders0/140/140/341/340/340/360/35
Hepatic encephalopathyNervous system disorders0/140/140/341/341/340/360/35
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPart A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B Placebo
HeadacheNervous system disorders4/143/143/343/347/3415/361/35
Oedema peripheralGeneral disorders2/141/144/345/349/3411/363/35
HypotensionVascular disorders2/141/142/343/345/343/360/35
DiarrhoeaGastrointestinal disorders0/142/140/342/340/342/362/35
FatigueGeneral disorders0/140/143/341/342/345/361/35
ConstipationGastrointestinal disorders0/140/142/342/341/345/361/35
DizzinessNervous system disorders1/141/144/341/340/342/363/35
Orthostatic hypotensionVascular disorders0/141/142/341/344/341/364/35
AscitesGastrointestinal disorders0/140/144/341/340/342/362/35
DyspnoeaRespiratory, thoracic and mediastinal disorders0/140/140/340/340/344/361/35

Baseline characteristics

Baseline Analysis Population is based on Full Analysis Set, defined as all participants who were randomised and received any IP.

Age, Continuous
Age, Continuous(Years)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
Mean62.2 ± 7.666.7 ± 11.760.6 ± 8.462.3 ± 10.761.7 ± 8.760.9 ± 8.459.7 ± 9.461.5 ± 9.3
Age, Customized
Age, Customized(Participants)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
>=18 - <30 years00010001
>=30 - <50 years113232416
>=50 - <65 years752216161818102
>=65 - <=80 years6891515161382
Missing00000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
Female53128981156
Male9112226252824145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
Hispanic or Latino414343120
Missing00002338
Not Hispanic or Latino10133031283031173
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
American Indian or Alaska Native00000000
Asian001433415
Black or African American00112206
Missing00000000
Native Hawaiian or other Pacific Islander00000000
Not reported00010102
Other001055415
White14143128242527163
Region of Enrollment
Region of Enrollment(Participants)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
Australia00101013
Austria223633625
Belgium00200002
China00121217
Czech Republic00011103
Denmark054205117
France00002349
Germany313533422
Netherlands00101114
Romania005432519
Spain5477129650
Switzerland12100138
Taiwan00011125
United Kingdom00013206
United States of America306533121
HVPG
HVPG(mmHg)Part A Zibo/Dapa 2.5 mg/10 mgPart A PlaceboPart B Dapa 10 mgPart B Zibo/Dapa 1 mg/10 mgPart B Zibo/Dapa 2.5 mg/10 mgPart B Zibo/Dapa 5 mg/10 mgPart B PlaceboTotal
Mean12.68 ± 3.7310.54 ± 3.5116.00 ± 4.2415.24 ± 3.3416.41 ± 3.7315.85 ± 3.7517.23 ± 3.6015.54 ± 4.05
08

Study locations

50 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Pasadena, California 91105, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    The Bronx, New York 10467, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Charlottesville, Virginia 22903, United States
  • Research Site
    Richmond, Virginia 23249, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Beijing, 100057, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310015, China
  • Research Site
    Prague, 128 00, Czechia
  • Research Site
    Prague, 169 02, Czechia
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Esbjerg, 6700, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Køge, 4600, Denmark
  • Research Site
    Angers, 49933, France
  • Research Site
    Clichy, 92110, France
  • Research Site
    Paris, 75651, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Landshut, 84034, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Wiesbaden, 65189, Germany
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Cluj-Napoca, 400162, Romania
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Bern, 3010, Switzerland
  • Research Site
    Lucerne, 6000, Switzerland
  • Research Site
    Lugano, 6900, Switzerland
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Birmingham, B9 5SS, United Kingdom
  • Research Site
    Cambridge, CB2 0XY, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in May 2025, 30 months.

Results were first posted in Sep 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 25, 2022
StartActual
Oct 31, 2022
Primary completionActual
May 22, 2025
CompletionActual
Jul 17, 2025
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPart A: Absolute changeChange in HVPG from baselineFrom Baseline to Week 6., Part ATime frame: at Week 6 → From Baseline to Week 6
  • EditedPart B: Absolute changeChange in HVPG from baselineFrom Baseline to Week 6., Part BTime frame: at Week 6 → From Baseline to Week 6
Sep 25, 2026
Documents
Secondary outcomes
10 edited, 10 added, 2 removed
What changed in the outcomes
  • EditedPart A: Percent change in HVPG from baselinePercentage Change From Baseline to Week 6., Part ATime frame: at Week 6 → From Baseline to Week 6
  • EditedPart A: Evaluation of changeChange in body weightBody Weight (kg) over time courseOver Time Course of study. Percentage and absolute change from baseline in body weight at Week 6.Study, Part ATime frame: at Week 6 → From baseline to Week 6
  • EditedPart A: Percentage and absolute changeChange in total dosageTotal Dosage of loopLoop-diuretic equivalents use from baselineEquivalents Use From Baseline to Week 6., Part ATime frame: at Week 6 → From baseline to Week 6
  • EditedPart A: Change in total body water, extracellular water and intracellular water volumes from baselineTotal Body Fat Mass From Baseline to Week 6. Change in total body fat mass from baseline to Week 6., Part ATime frame: at Week 6 → From baseline to Week 6
  • EditedPart A: Change in systolic and diastolic blood pressure from baselineTotal Body Water From Baseline to Week 6., Part ATime frame: at Week 6 → From Baseline to Week 6
  • EditedPart B:HVPG Percentage change in HVPG from baselineChange From Baseline to Week 6., Part BTime frame: at Week 6 → From baseline to week 6
  • EditedPart B: Evaluation of changeChange in body weightBody Weight (kg) over time courseOver Time Course of study. Percentage and absolute change from baseline in body weight at Week 6 and Week 16.Study, Part BTime frame: at Week 6 and Week 16 → From baseline to Week 6 and Week 16
  • EditedPart B: Absolute changeChange in total dosageTotal Dosage of loopLoop-diuretic equivalents use from baselineEquivalents Use From Baseline to Week 6 and Week 16., Part BTime frame: at Week 6 and Week 16 → From Baseline to Week 6 and Week 16
  • EditedPart B: Change in total body water, extracellular water and intracellular water volumes from baselineTotal Body Water From Baseline to Week 6 and Week 16. Change in total body fat mass from baseline to Week 6 and Week 16., Part BTime frame: at Week 6 and Week 16 → From Baseline to Week 6 and Week 16
  • EditedPart B: Change in systolic and diastolic blood pressure from baselineExtracellular Water From Baseline to Week 6 and Week 16., Part BTime frame: at Week 6 and Week 16 → From Baseline to Week 6 and to Week 16
  • AddedNumber of Participants With HVPG Response at Week 6, Part ATime frame: From baseline to week 6
  • AddedNumber of Participants With HVPG Response at Week 6, Part BTime frame: From baseline to Week 6
  • AddedChange in Extracellular Water From Baseline to Week 6, Part ATime frame: From baseline to Week 6
  • AddedChange in Intracellular Water From Baseline to Week 6, Part ATime frame: From Baseline to Week 6
  • AddedChange in Intracellular Water From Baseline to Week 6 and Week 16, Part BTime frame: From Baseline to Week 6 and Week 16
  • AddedChange in Total Body Fat Mass From Baseline to Week 6 and Week 16, Part BTime frame: From Baseline to Week 6 and Week 16
  • AddedChange in Systolic Blood Pressure From Baseline to Week 6, Part ATime frame: From Baseline to Week 6
  • AddedChange in Systolic Blood Pressure From Baseline to Week 6 and Week 16, Part BTime frame: From baseline to Week 6 and Week 16
  • AddedChange in Diastolic Blood Pressure From Baseline to Week 6, Part ATime frame: From Baseline to Week 6
  • AddedChange in Diastolic Blood Pressure From Baseline to Week 6 and Week 16, Part BTime frame: From baseline to Week 6 and Week 16
  • RemovedPart A: HVPG response, where a responder is defined as HVPG < 10 mmHg or a reduction in HVPG of ≥ 1.5 mmHg from baseline to Week 6.Time frame: at Week 6
  • RemovedPart B: HVPG response, where a responder is defined as at least 20% decrease or a reduction to or below 12 mmHg in HVPG from baseline to Week 6.Time frame: at Week 6
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPart A: Absolute changeChange in HVPG from baselineFrom Baseline to Week 6., Part ATime frame: at Week 6 → From Baseline to Week 6
    • EditedPart B: Absolute changeChange in HVPG from baselineFrom Baseline to Week 6., Part BTime frame: at Week 6 → From Baseline to Week 6
    Secondary outcomes 10 edited, 10 added, 2 removed
    What changed in the outcomes
    • EditedPart A: Percent change in HVPG from baselinePercentage Change From Baseline to Week 6., Part ATime frame: at Week 6 → From Baseline to Week 6
    • EditedPart A: Evaluation of changeChange in body weightBody Weight (kg) over time courseOver Time Course of study. Percentage and absolute change from baseline in body weight at Week 6.Study, Part ATime frame: at Week 6 → From baseline to Week 6
    • EditedPart A: Percentage and absolute changeChange in total dosageTotal Dosage of loopLoop-diuretic equivalents use from baselineEquivalents Use From Baseline to Week 6., Part ATime frame: at Week 6 → From baseline to Week 6
    • EditedPart A: Change in total body water, extracellular water and intracellular water volumes from baselineTotal Body Fat Mass From Baseline to Week 6. Change in total body fat mass from baseline to Week 6., Part ATime frame: at Week 6 → From baseline to Week 6
    • EditedPart A: Change in systolic and diastolic blood pressure from baselineTotal Body Water From Baseline to Week 6., Part ATime frame: at Week 6 → From Baseline to Week 6
    • EditedPart B:HVPG Percentage change in HVPG from baselineChange From Baseline to Week 6., Part BTime frame: at Week 6 → From baseline to week 6
    • EditedPart B: Evaluation of changeChange in body weightBody Weight (kg) over time courseOver Time Course of study. Percentage and absolute change from baseline in body weight at Week 6 and Week 16.Study, Part BTime frame: at Week 6 and Week 16 → From baseline to Week 6 and Week 16
    • EditedPart B: Absolute changeChange in total dosageTotal Dosage of loopLoop-diuretic equivalents use from baselineEquivalents Use From Baseline to Week 6 and Week 16., Part BTime frame: at Week 6 and Week 16 → From Baseline to Week 6 and Week 16
    • EditedPart B: Change in total body water, extracellular water and intracellular water volumes from baselineTotal Body Water From Baseline to Week 6 and Week 16. Change in total body fat mass from baseline to Week 6 and Week 16., Part BTime frame: at Week 6 and Week 16 → From Baseline to Week 6 and Week 16
    • EditedPart B: Change in systolic and diastolic blood pressure from baselineExtracellular Water From Baseline to Week 6 and Week 16., Part BTime frame: at Week 6 and Week 16 → From Baseline to Week 6 and to Week 16
    • AddedNumber of Participants With HVPG Response at Week 6, Part ATime frame: From baseline to week 6
    • AddedNumber of Participants With HVPG Response at Week 6, Part BTime frame: From baseline to Week 6
    • AddedChange in Extracellular Water From Baseline to Week 6, Part ATime frame: From baseline to Week 6
    • AddedChange in Intracellular Water From Baseline to Week 6, Part ATime frame: From Baseline to Week 6
    • AddedChange in Intracellular Water From Baseline to Week 6 and Week 16, Part BTime frame: From Baseline to Week 6 and Week 16
    • AddedChange in Total Body Fat Mass From Baseline to Week 6 and Week 16, Part BTime frame: From Baseline to Week 6 and Week 16
    • AddedChange in Systolic Blood Pressure From Baseline to Week 6, Part ATime frame: From Baseline to Week 6
    • AddedChange in Systolic Blood Pressure From Baseline to Week 6 and Week 16, Part BTime frame: From baseline to Week 6 and Week 16
    • AddedChange in Diastolic Blood Pressure From Baseline to Week 6, Part ATime frame: From Baseline to Week 6
    • AddedChange in Diastolic Blood Pressure From Baseline to Week 6 and Week 16, Part BTime frame: From baseline to Week 6 and Week 16
    • RemovedPart A: HVPG response, where a responder is defined as HVPG < 10 mmHg or a reduction in HVPG of ≥ 1.5 mmHg from baseline to Week 6.Time frame: at Week 6
    • RemovedPart B: HVPG response, where a responder is defined as at least 20% decrease or a reduction to or below 12 mmHg in HVPG from baseline to Week 6.Time frame: at Week 6
    + 4 other changes: index terms, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05516498
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Oct 31, 2022
Primary completion
May 22, 2025
Completion
Jul 17, 2025
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZD4054 · Dapagliflozin

Start the discussion